Business Context and Reporting Period
This Form 8-K filing by Frequency Therapeutics, Inc. (trading symbol: FREQ) reports on the Annual Meeting of Stockholders held on June 21, 2022. The company is incorporated in Delaware and is classified as an emerging growth company. The report details the voting outcomes for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.
Material Changes and Voting Results
The meeting saw 21,573,262.78 shares present, representing approximately 61.7% of outstanding common stock. The following proposals were approved:
- Item 1 (Director Elections): Timothy J. Barberich and Robert S. Langer were elected as Class III directors to serve until the 2025 Annual Meeting.
- Item 2 (Auditor Ratification): The appointment of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2022, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural results of the shareholder vote.
Investor Verification Checklist
- Verify the full composition of the Board of Directors following the election of Timothy J. Barberich and Robert S. Langer.
- Confirm the engagement terms and scope of work with the newly ratified auditor, RSM US LLP.
- Review the Definitive Proxy Statement filed on April 29, 2022, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.